Please login to the form below

Not currently logged in
Email:
Password:

ataluren

This page shows the latest ataluren news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK backs Evox dystrophin delivery project

Duchenne UK backs Evox dystrophin delivery project

At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren)   and Sarepta’s Exondys 51 (eteplirsen) –

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m. ... Ataluren was in clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations. But again, a similar failure in a six minute

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics